You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Recurrent or refractory malignant lymphoma or Hodgkin's disease.

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma Trial in

Active, not recruiting
Has Results
  • Metastatic Melanoma
  • +22 more
  • Ipilimumab
  • +3 more
  • Birmingham, Alabama
  • +24 more
Jan 19, 2023

AIDS-Related Non-Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8 Trial in United

Recruiting
  • AIDS-Related Non-Hodgkin Lymphoma
  • +29 more
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Birmingham, Alabama
  • +12 more
Aug 4, 2022

Adenoid Cystic Skin Carcinoma, Adnexal Carcinoma, Anaplastic Large Cell Lymphoma, ALK-Negative Trial in United States

Recruiting
  • Adenoid Cystic Skin Carcinoma
  • +38 more
  • Biopsy
  • +6 more
  • Los Angeles, California
  • +35 more
Jan 31, 2023

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Recruiting
  • Recurrent Childhood Acute Myeloid Leukemia
  • +17 more
    • Miami, Florida
      Nicklaus Children's Hospital
    May 13, 2023

    Advanced Malignant Solid Tumor, Anal Carcinoma, HIV Infection Trial in Australia, United States (Ipilimumab, Nivolumab)

    Recruiting
    • Advanced Malignant Solid Neoplasm
    • +8 more
    • Ipilimumab
    • Nivolumab
    • La Jolla, California
    • +34 more
    Nov 29, 2022

    Recurrent/Refractory Classical Hodgkin's Lymphoma Trial in Tianjin (AK105,Anrotinib HCl)

    Enrolling by invitation
    • Recurrent/Refractory Classical Hodgkin's Lymphoma
    • AK105，Anrotinib hydrochloride
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Insititute & Hospital
    Jan 12, 2023

    Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides Trial in United

    Recruiting
    • Folliculotropic Mycosis Fungoides
    • +7 more
    • Durvalumab
    • +2 more
    • Duarte, California
    • +3 more
    Jan 12, 2023

    Colorectal Carcinoma, Endometrial Carcinoma, Melanoma Trial in United States (Tegavivint)

    Recruiting
    • Colorectal Carcinoma
    • +21 more
    • Dual X-ray Absorptiometry
    • +2 more
    • Birmingham, Alabama
    • +18 more
    Jan 30, 2023

    Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma Trial in Changsha (BEBT-908 for

    Completed
    • Relapsed or Refractory Non-Hodgkin's Lymphoma
    • Relapsed or Refractory Multiple Myeloma
    • BEBT-908 for injection
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Oct 9, 2023

    Ex Vivo Drug Sensitivity Testing and Mutation Profiling

    Completed
    • Recurrent Childhood Acute Myeloid Leukemia
    • +13 more
      • Miami, Florida
        Nicklaus Children's Hospital
      Jan 18, 2023

      Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Grade 1

      Active, not recruiting
      • Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
      • +18 more
      • Anti-ICOS Monoclonal Antibody MEDI-570
      • +2 more
      • Duarte, California
      • +22 more
      Jan 18, 2023

      Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma Trial in Zhengzhou, Shengyang, Hangzhou (HRS-3738)

      Recruiting
      • Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
      • Zhengzhou, Henan, China
      • +2 more
      Jul 27, 2022

      Recurrent Histiocytic and Dendritic Cell Tumor, Recurrent Non-Hodgkin Lymphoma, Refractory Histiocytic and Dendritic Cell Tumor

      Recruiting
      • Recurrent Histiocytic and Dendritic Cell Neoplasm
      • +3 more
      • Rochester, Minnesota
        Mayo Clinic in Rochester
      Dec 5, 2022

      Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

      Active, not recruiting
      • Recurrent Anaplastic Large Cell Lymphoma
      • +10 more
      • Houston, Texas
        M D Anderson Cancer Center
      Jan 30, 2023

      Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in Changsha, Suzhou (U16)

      Recruiting
      • Relapsed or Refractory Non-Hodgkin's Lymphoma
      • Changsha, Hunan, China
      • +1 more
      Mar 13, 2023

      NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Hubei (autologous NK cell)

      Not yet recruiting
      • NK Cell
      • +2 more
      • autologous NK cell
      • Hubei, Xiangyang, China
        EC of Xiangyang No.1 People's Hospital Hubei University of Medic
      Jun 19, 2023

      Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

      Recruiting
      • Recurrent Anaplastic Large Cell Lymphoma
      • +9 more
      • Anti-CD30/CD16A Monoclonal Antibody AFM13
      • +4 more
      • Houston, Texas
        M D Anderson Cancer Center
      Aug 9, 2022

      Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker

      Suspended
      • Recurrent Aggressive Non-Hodgkin Lymphoma
      • +5 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Rochester, Minnesota
        Mayo Clinic in Rochester
      Jan 12, 2023

      Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

      Recruiting
      • Relapsed or Refractory Hodgkin Lymphoma
      • Beijing, Beijing, China
        Han wei dong
      Jun 14, 2023

      Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic

      Not yet recruiting
      • Recurrent Transformed Chronic Lymphocytic Leukemia
      • +7 more
      • Biospecimen Collection
      • +9 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      May 15, 2023

      Cardiovascular Events Among Adults Relapsed or Refractory

      Recruiting
      • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
      • +9 more
      • Electronic Health Record Review
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 5, 2022

      Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma Trial in Boston (Nivolumab, Ipilimumab)

      Recruiting
      • Hodgkin Lymphoma
      • +2 more
      • Boston, Massachusetts
      • +2 more
      Oct 18, 2022

      Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,

      Recruiting
      • Recurrent Hodgkin Lymphoma
      • +3 more
      • Brentuximab Vedotin
      • +2 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Oct 4, 2022

      Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

      Not yet recruiting
      • Classical Hodgkin Lymphoma
      • Non-Hodgkin Lymphoma
      • GEN3017
      • (no location specified)
      Aug 25, 2023

      Hodgkin Lymphoma Trial in Moscow (Nivolumab)

      Recruiting
      • Hodgkin Lymphoma
      • Moscow, Russian Federation
        The Federal Budget-Funded Institution National Medical Surgical
      Oct 31, 2022